Maintenance Therapy of Busulfan-Induced Chronic Granulocytic Leukemia Remissions with Interferon-α2b

  • D. E. Bergsagel
Conference paper


There has been little improvement in our ability to alter the course and survival of patients with chronic granulocytic leukemia (CGL) during the past 50 years. Many forms of treatment, such as busulfan, hydroxyurea, dibromomannitol, melphalan, mercaptopurine, thioguanine, and splenic irradiation, are effective in controlling the manifestations of CGL during the chronic phase, but none of these agents delays the onset of the blast phase or prolongs survival.


Toxicity Depression Leukemia Interferon Melphalan 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Galton DAG (1959) Treatment of the chronic leukemias. Br Med Bull 15: 78–85PubMedGoogle Scholar
  2. 2.
    Bergsagel DE (1967) The chronic leukemias: a review of disease manifestations and the aims of treatment. Can Med Assoc J 96: 1616–1620Google Scholar
  3. 3.
    Taetle R, Buick RN, McCulloch EA (1980) Effect of interferon on colony-formation in culture by blast cell progenitors in acute myeloblasts leukemia. Blood 56: 549–552PubMedGoogle Scholar
  4. 4.
    Talpaz M, McCredie KB, Mavlight GM, Gutterman JU (1983) Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia. Blood 62: 689–692PubMedGoogle Scholar
  5. 5.
    Talpaz M, Kantarjian HM, McCredie KB, Trujillio JM, Keating MJ, Gutterman JU (1986) Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha 2a in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069PubMedCrossRefGoogle Scholar
  6. 6.
    Samid D, Chang EH, Friedman RM (1984) Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun 119: 21–28PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • D. E. Bergsagel

There are no affiliations available

Personalised recommendations